Promising Clinical Updates and Strong Safety Profile Support Buy Rating for Perspective Therapeutics

Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report) and keeping the price target at $18.00.

Justin Walsh has given his Buy rating due to a combination of factors related to the promising clinical updates from Perspective Therapeutics’ Pb-212-VMT-α-NET program. The recent data presented at the 2025 ASCO Annual Meeting showed a favorable efficacy trend, with 57% of neuroendocrine tumor patients responding positively to the treatment, which is an improvement from previous updates. This response rate is comparable to a competitor’s treatment, alleviating concerns about its efficacy.
Furthermore, the treatment has demonstrated a strong safety profile, with no dose-limiting toxicities or severe adverse events related to the treatment reported among the 42 patients dosed. The absence of serious side effects, along with the ongoing discussions with the FDA about potential dose escalation, supports the potential for further positive developments. The company’s solid cash position also provides a stable financial foundation, reinforcing the Buy rating with a price target of $18.

In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $15.00 price target.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CATX in relation to earlier this year.